Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Relvar Ellipta
25% more patients improve asthma control vs. other ICS/LABAs in everyday clinical practice. 1
Trelegy▼ Ellipta
Discover more about the only once daily COPD single inhaler triple therapy available in Ireland. 2
Anoro▼ Ellipta
Discover more about the only once-daily LAMA/LABA to demonstrate superiority in lung function within the class. 3
Incruse Ellipta
Incruse Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD 4
Relvar Ellipta
25% more patients improve asthma control vs. other ICS/LABAs in everyday clinical practice. 1
Trelegy▼ Ellipta
Discover more about the only once daily COPD single inhaler triple therapy available in Ireland. 2
Anoro▼ Ellipta
Discover more about the only once-daily LAMA/LABA to demonstrate superiority in lung function within the class. 3
Incruse Ellipta
Incruse Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD 4
More Information
Zejula▼ (niraparib) patient booklet available to order online
This Zejula patient booklet has been developed to provide information on some of the questions patients prescribed Zejula may have and helps to support them on their treatment journey. 7
Using dual therapy or triple therapy for your patients?
The IMPACT trial was the first trial to assess the efficacy and safety of single inhaler Triple Therapy TRELEGY▼ Ellipta vs. an ICS/LABA (FF/VI 92/22 mcg) and a LAMA/LABA (UMEC/VI). 8
Abbreviations
FEV1, forced expiratory volume in one second; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol
References:
- Woodcock A et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel-group, randomised controlled trial. Lancet 2017;290:22247-2255.
- Trelegy Ellipta SmPC 2020. Available at www.medicines.ie. Last accessed July 2021
- Anoro Ellipta Summary of Product Characteristics. Available from: medicines.ie. Accessed July 2021
- Incruse Ellipta Summary of Product Characteristics. Available from: medicines.ie. Accessed July 2021
- Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
- van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243
- Zejula Summary of Product Characteristics. Available from: www.medicines.ie. Accessed July 2021
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Trade marks are owned by or licensed to the GSK group of companies.
